ARTORG Center for Biomedical Engineering Research


2024/03/21 | Grants & Awards | Artificial Intelligence

FDA Registration PeriVision VisionOne

PeriVision, a spin-off from the ARTORG Center and the Inselspital, Bern University Hospital, proudly announces its recent FDA registration for its first medical software product VisionOne. This significant milestone marks a pivotal moment in PeriVision's mission to enhance patient care and revolutionize the field of ophthalmology.

VisionOne being used in ophthalmology practice Genève Ophtalmologie, Geneva, Switzerland. (© PeriVision)

With VisionOne, ophthalmologists and optometrists can easily configure eye tests on portable VR headsets and subsequently analyze the results on a cloud platform. In the back-end AI algorithms optimize the eye tests, automate assistance, control quality and provide valuable insights for clinical decisions.

The FDA registration underscores PeriVision's commitment to meeting the highest standards of safety, efficacy, and quality in its medical software according to Dr. Ernest Cavin, a PeriVision board member with a long career in ophthalmology, most recently as CEO of Haag-Streit USA.

"We are thrilled to receive FDA registration for our latest medical device," said Dr. Ernest Cavin. "This milestone represents the culmination of years of research, development, and collaboration with leading institutions. We are confident that this technology will significantly impact the way eye tests are performed, ultimately improving patient outcomes."

PeriVision's FDA-registered device combines cutting-edge technologies such as AI, VR and eye tracking to address the needs of ophthalmologists, optometrists and their patients. PeriVision’s first product addresses the unmet clinical need for more efficient visual field testing, a routine eye test for glaucoma diagnosis and monitoring. With over 80 million living with the disease, glaucoma is the leading cause of irreversible blindness globally. Dr. Kevin Gillmann, PeriVision’s Chief Medical Officer and a glaucoma specialist himself, emphasizes that this market registration is the starting point on a longer-term roadmap.

“We want to develop a holistic platform comprising a portfolio of eye tests and AI tools to assist ophthalmologists and optometrists in their daily work. Our ultimate goal is to build software tools that improve patient experience, disease management and clinic productivity. ”

With its approval, healthcare providers can now confidently integrate this innovative solution into their practice, offering patients access to state-of-the-art care.

For more information about PeriVision and its FDA-registered medical software system, please visit or contact